Soft Tissue Sarcoma Pipeline Gains Momentum: 70+ Companies Advance 75+ Therapies Across All Development Stages
核心洞察
Over 70 companies are actively developing more than 75 pipeline therapies for soft tissue sarcoma (搜索), a rare malignancy representing less than 1% of adult cancers.
Philogen's Fibromun (L19TNF) plus doxorubicin has reached Phase III, while Chipscreen's chiauranib and Lyvgen's LVGN6051 with anlotinib advance through Phase II and Phase I/II respectively.
Sun Yat-sen University (搜索) initiated a study in June 2026 evaluating anlotinib as maintenance therapy following first-line anthracycline-based chemotherapy in advanced soft tissue sarcoma (搜索).
The soft tissue sarcoma (搜索) (STS) therapeutic pipeline is experiencing unprecedented growth, with more than 70 companies actively advancing over 75 pipeline therapies, according to DelveInsight's "Soft Tissue Sarcoma Pipeline Insight 2026" report. This surge in research activity addresses a rare but challenging group of malignancies that, while accounting for less than 1% of all adult cancers, represent approximately 7% of childhood cancers and encompass over 50 distinct histological subtypes.
Soft tissue sarcomas arise from mesenchymal tissues including muscles, fat, blood vessels, nerves, tendons, and joint linings. These tumors most frequently develop in the arms, legs, and abdomen, and their clinical presentation varies widely depending on tumor size, location, and subtype. Early-stage disease often remains asymptomatic, complicating timely detection. As tumors progress, patients may experience noticeable lumps or swelling, pain from nerve or muscle compression, and in abdominal cases, digestive disturbances. Advanced disease can produce systemic symptoms including weight loss and fatigue.
Late-Stage Development: Fibromun Combination Approaches Pivotal Data
Philogen S.p.A. (搜索) leads the late-stage pipeline with Fibromun (L19TNF), a fully-human immunomodulatory product currently in Phase III development. Fibromun consists of the L19 antibody fused to tumor necrosis factor (TNF), a potent pro-inflammatory cytokine. The L19 antibody specifically targets the EDB domain of fibronectin, enabling selective tumor localization while sparing healthy tissues. According to the report, Fibromun has demonstrated potent anti-tumor activity both as a single agent and in combination with other drugs across multiple immunocompetent preclinical models, inducing long-lasting complete responses in most cases. The Phase III program is evaluating Fibromun in combination with doxorubicin.
Mid-Stage Advances: Chiauranib's Triple-Pathway Mechanism
Chipscreen Biosciences (搜索) is advancing chiauranib, a highly selective Aurora B/VEGFR (搜索)/PDGFR/c-Kit/CSF1R (搜索) inhibitor, through Phase II clinical development. The drug was specifically designed to address drug resistance through a triple-pathway mechanism that simultaneously inhibits tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment. Preclinical data suggest chiauranib has outperformed drugs with similar mechanisms in pharmacodynamic activity in animal studies, while maintaining a favorable safety profile.
Early-Stage Innovation: Conditional T-Cell Activation
Lyvgen Biopharma Holdings Limited is developing exlinkibart (LVGN6051), an anti-CD137/4-1BB (搜索) agonistic monoclonal antibody with conditional activation through selective Fcγ-receptor IIB binding for targeted immune activation within the tumor microenvironment. LVGN6051 has achieved a recommended Phase II dose of 4 mg/kg every three weeks, demonstrating desirable pharmacokinetic and pharmacodynamic properties, an acceptable safety profile, and durable objective responses in heavily pre-treated patients with various solid tumors. The agent is currently in Phase I/II development for soft tissue sarcoma (搜索) in combination with anlotinib. Registration clinical trials are planned across melanoma, sarcoma, and head and neck cancers.
Recent Clinical Trial Activity
On June 12, 2026, Sun Yat-sen University (搜索) initiated a study evaluating the safety and efficacy of anlotinib as maintenance treatment after first-line anthracycline-based chemotherapy in advanced soft tissue sarcoma (搜索). Anlotinib, a multi-target receptor tyrosine kinase inhibitor, targets angiogenesis-related kinases including VEGFR (搜索), FGFR, PDGFR, and the tumor cell proliferation-related kinase c-Kit. The drug has already received approval as a second-line therapeutic agent for metastatic soft tissue sarcoma based on the ALTER-0203 clinical trial.
On June 10, 2026, Alexander Z. Wei, MD launched a Phase II clinical trial evaluating the safety and efficacy of adding APX005M, a CD40 (搜索) agonistic monoclonal antibody, to doxorubicin for patients with advanced soft tissue sarcoma (搜索). The investigators hypothesize that doxorubicin, the current standard of care for most advanced sarcomas, may demonstrate enhanced efficacy when combined with this immunotherapeutic approach.
Diverse Therapeutic Landscape
The pipeline encompasses a broad range of therapeutic modalities including monoclonal antibodies, small molecules, peptides, polymers, and gene therapies. Routes of administration span oral, parenteral, intravenous, subcutaneous, and topical formulations. Key companies driving innovation include Philogen S.p.A. (搜索), Chipscreen Biosciences (搜索), Lyvgen Biopharma, Advenchen Laboratories, OncoTherapy Science, Washington University School of Medicine, Sun Yat-sen University (搜索), QBiotics Group, Thermosome GmbH, Intensity Therapeutics, Centre Leon Berard, Institut Claudius Regaud, and Base Therapeutics. Additional pipeline therapies under investigation include bevacizumab, MGCD516, pazopanib hydrochloride, liposomal vincristine, AdAPT-001, rubitecan, ridaforolimus, and OMBRABULIN (AVE8062).